search
Back to results

Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial (MULTI-EXA)

Primary Purpose

Acute Exacerbation of COPD

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Personalized antibiotic treatment
Usual antibiotic treatment
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Exacerbation of COPD focused on measuring AECOPD, respiratory multiplex PCR, Appearance of sputum, Procalcitonin, Antibiotics saving, Diagnosis, Treatment

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years old
  • COPD (according to GOLD 2020), whatever the stage (I-IV)
  • Acute exacerbation (according to GOLD 2020: acute worsening of respiratory symptoms that result in additional therapy) with acute respiratory failure requiring admission to ICU and ventilatory support (invasive mechanical ventilation or non-invasive mechanical ventilation or high-flow nasal oxygen therapy with FiO2 ≥ 50%)
  • Informed consent of patient, patient's immediate family/ or inclusion in an emergency situation
  • Affiliation to a social security

Exclusion Criteria:

  • The interval between admission to the hospital and admission to ICU more than 3 days
  • Antibiotic therapy clearly needed for a suspected or documented extra-respiratory infection
  • Congenital or acquired immunosuppression (congenital immune deficiency, high-grade hematologic malignancies, use of immunosuppressive drugs in the last 30 days including anti-cancer chemotherapy and antirejection medications, corticosteroid treatment ≥ 20 mg/d prednisone equivalent for at least 14 days, neutropenia, HIV with unknown or known CD4 <200 / µL in the past 6 months)
  • Tracheotomy
  • Bronchiectasis / cystic fibrosis
  • Moribund patient (imminent death)
  • Patient deprived of liberty and / or under legal protection measure
  • Patient already included in MULTI-EXA
  • Patient already included in a type 1 interventional study
  • Ongoing pregnancy

Sites / Locations

  • Intensive care department-Hospital TenonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Personalized strategy

Usual strategy

Arm Description

Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum. A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion. After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7. This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using: The appearance of sputum (clinical approach); PCT values and kinetics (biological approach); Results of mPCR FA-PPP (microbiological approach).

Usual antibiotic treatment Left at the discretion of the physician as in usual practice

Outcomes

Primary Outcome Measures

Number of antibiotic-free days
The number of days alive without antibiotics at Day 28.

Secondary Outcome Measures

Number of days with antibiotics in survivors at D28
Number of days with broad spectrum antibiotics in survivors at D28
Nosocomial pneumonia incidence rate
Multidrug-resistant bacteria colonization / infection rate
ICU lengths of stay
Hospital lengths of stay
Number of days alive without mechanical ventilation (invasive or non-invasive)
Incidence rates of Hospital-acquired pneumonia (including ventilator-associated pneumonia)
Mortality rates (in ICU, in hospital)
Number of additional AECOPD (requiring hospitalization and / or initiation of systemic corticosteroid therapy and / or antibiotic therapy) after the initial AECOPD
Time between the initial AECOPD and the following AECOPD (AECOPD requiring hospitalization and / or initiation of systemic corticosteroid therapy and / or antibiotic therapy)
COPD-related symptoms
Using the COPD Assessment Test (CAT) questionnaire

Full Information

First Posted
March 4, 2022
Last Updated
July 28, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
BioMérieux
search

1. Study Identification

Unique Protocol Identification Number
NCT05280132
Brief Title
Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial
Acronym
MULTI-EXA
Official Title
Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 8, 2022 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
BioMérieux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
COPD is a common chronic disease. Its natural course is characterized by Acute exacerbations (AE). This may require hospitalization or even ICU/RESUSCITATION admission. The most common causes are respiratory distress with hypercapnic acidosis that requires mechanical ventilation (Invasive or non-invasive). Lower respiratory tract infections, bacteria and/or viruses are the main pathogenic factors of AE. The treatment of AECOPD is initially symptomatic treatment, combining bronchodilators, ventilatory support (oxygen therapy and/or mechanical ventilation) and respiratory physiotherapy. Systemic corticosteroid therapy is optional. When i) the sputum is purulent and ii) increased dyspnea and / or an increase in sputum volume is observed, antibiotic treatment is recommended for hospitalized patients. Antibiotic therapy is routinely recommended when mechanical ventilation is required. During ICU/RESUSCITATION AECOPD, more than 85% of patients received antibiotic therapy, with a median duration of 8 to 9 days, and the benefit of antibiotic therapy is likely to be limited to infected patients. Suspected or documented lower respiratory tract bacteria, that is, 25% to 50% of patients. This will lead to overuse of antibiotics, which is a problem for patients and the community. A personalized antibiotic strategy could limit this phenomenon, relying on multimodal methods, using aspect of sputum (clinical method), procalcitonin (PCT) (biological method) and the FilmArray ™ Pneumonia Panel extended panel multiplex respiratory PCR Plus (mPCR FA-PPP) (Biomérieux®) (microbiological approach). The hypothesis of this study is that sputum appearance, procalcitonin (PCT) and the FilmArray ™ Pneumonia Panel Plus expanded panel multiplex respiratory PCR (mPCR FA-PPP) (Biomérieux®) could be used in combination , and their results integrated into a decision-making algorithm aimed at personalizing antibiotic therapy and guiding its early termination in patients admitted to ICU/RESUSCITATION due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD) to the main benefit of antibiotic savings, and without additional risk to patient safety.
Detailed Description
Inclusion (D0_H0) is performed in ICU/RESUSCITATION. The interval between admission to the hospital and admission to ICU/RESUSCITATION must be maximum 72 hours. Conventional microbiological investigations are left at the discretion of the physicians, and may include blood cultures, L. pneumophila and S. pneumoniae antigens. Usual biology includes procalcitonin measurement. Empirical antimicrobial therapy must be started as soon as possible after inclusion. Randomization is performed immediately after the inclusion. In the intervention arm, a broad panel respiratory mPCR FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics and also aspect of sputum will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7. In the control arm, the antimicrobial therapy is left at the discretion of the physicians, as in usual practice. Evaluation criteria are collected at hospital discharge or at D28, and D90. The vital status may be obtained by phone call at D28 (if the patient has been discharged before D28) and at D90.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Exacerbation of COPD
Keywords
AECOPD, respiratory multiplex PCR, Appearance of sputum, Procalcitonin, Antibiotics saving, Diagnosis, Treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
204 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Personalized strategy
Arm Type
Experimental
Arm Description
Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum. A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion. After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7. This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using: The appearance of sputum (clinical approach); PCT values and kinetics (biological approach); Results of mPCR FA-PPP (microbiological approach).
Arm Title
Usual strategy
Arm Type
Other
Arm Description
Usual antibiotic treatment Left at the discretion of the physician as in usual practice
Intervention Type
Procedure
Intervention Name(s)
Personalized antibiotic treatment
Intervention Description
Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum.
Intervention Type
Other
Intervention Name(s)
Usual antibiotic treatment
Intervention Description
The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
Primary Outcome Measure Information:
Title
Number of antibiotic-free days
Description
The number of days alive without antibiotics at Day 28.
Time Frame
Day 28
Secondary Outcome Measure Information:
Title
Number of days with antibiotics in survivors at D28
Time Frame
Day 28
Title
Number of days with broad spectrum antibiotics in survivors at D28
Time Frame
Day 28
Title
Nosocomial pneumonia incidence rate
Time Frame
Day 28
Title
Multidrug-resistant bacteria colonization / infection rate
Time Frame
Day 28
Title
ICU lengths of stay
Time Frame
Day 28
Title
Hospital lengths of stay
Time Frame
Day 28
Title
Number of days alive without mechanical ventilation (invasive or non-invasive)
Time Frame
Day 28
Title
Incidence rates of Hospital-acquired pneumonia (including ventilator-associated pneumonia)
Time Frame
Day 28
Title
Mortality rates (in ICU, in hospital)
Time Frame
Day 28 and Day 90
Title
Number of additional AECOPD (requiring hospitalization and / or initiation of systemic corticosteroid therapy and / or antibiotic therapy) after the initial AECOPD
Time Frame
Day 90
Title
Time between the initial AECOPD and the following AECOPD (AECOPD requiring hospitalization and / or initiation of systemic corticosteroid therapy and / or antibiotic therapy)
Time Frame
Day 90
Title
COPD-related symptoms
Description
Using the COPD Assessment Test (CAT) questionnaire
Time Frame
Day 90

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old COPD (according to GOLD 2020), whatever the stage (I-IV) Acute exacerbation (defined as the onset or worsening of one or more of the usual signs/symptoms of COPD) with acute worsening of respiratory symptoms that result in additional therapy) with acute respiratory failure requiring admission to ICU and ventilatory support (invasive mechanical ventilation or non-invasive mechanical ventilation or high-flow nasal oxygen therapy with FiO2 ≥ 50%) Informed consent of patient, patient's immediate family/ or inclusion in an emergency situation Affiliation to a social security Exclusion Criteria: The interval between admission to the hospital and admission to ICU more than 3 days Antibiotic therapy clearly needed for a suspected or documented extra-respiratory infection Congenital or acquired immunosuppression (congenital immune deficiency, high-grade hematologic malignancies, use of immunosuppressive drugs in the last 30 days including anti-cancer chemotherapy and antirejection medications, corticosteroid treatment ≥ 20 mg/d prednisone equivalent for at least 14 days, neutropenia, HIV with unknown or known CD4 <200 / µL in the past 6 months) Tracheotomy Bronchiectasis / cystic fibrosis Moribund patient (imminent death) Patient deprived of liberty and / or under legal protection measure Patient already included in MULTI-EXA Patient already included in a type 1 interventional study on antibiotics Ongoing pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guillaume VOIRIOT, MD, PhD
Phone
01 56 01 62 63
Email
guillaume.voiriot@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Muriel Fartoukh, PU-PH
Phone
01 56 01 65 72
Email
muriel.fartoukh@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillaume VOIRIOT, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Intensive care department-Hospital Tenon
City
Paris
ZIP/Postal Code
75020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume VOIRIOT, MD, PhD
Phone
01 56 01 62 63
Email
guillaume.voiriot@aphp.fr
First Name & Middle Initial & Last Name & Degree
Muriel FARTOUKH, PU-PH
Phone
01 56 01 65 72
Email
muriel.fartoukh@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual-participant data will be made available outside the primary research group for secondary research purposes like re-analysis, secondary analysis, or meta-analysis, and shared via an online secured platform.

Learn more about this trial

Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial

We'll reach out to this number within 24 hrs